GlassScriptPhysician profile
Harry T Garrett
NPI 1871589515
$6,266.43
in general payments reported to CMS, 2019-2025
37 companies · $757 in 2025
The $757 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $775 · 2020: $746 · 2021: $1,157 · 2022: $919 · 2023: $849 · 2024: $1,063 · 2025: $757.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,669.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,669.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,105.62 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $627.01 | 2019-2025 | Rybelsus, Ozempic |
| Novartis Pharmaceuticals Corporation | $623.58 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $619.58 | 2019-2025 | Verquvo, Belsomra, Steglatro |
| Lilly USA, LLC | $565.96 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $482.40 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $419.59 | 2019-2025 | Jardiance, Tradjenta |
| Glaxosmithkline, LLC. | $216.57 | 2019-2024 | Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $190.61 | 2019-2022 | |
| Mylan Specialty L.P. | $173.12 | 2020-2024 | Yupelri |
| Bayer Healthcare Pharmaceuticals INC. | $133.51 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $130.87 | 2019-2023 | Eliquis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $89.47 | 2019-2022 | |
| Amarin Pharma, INC. | $86.95 | 2021-2022 | |
| Esperion Therapeutics, INC. | $85.05 | 2020-2024 | Nexletol |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $75.71 | 2021-2024 | Dexcom G6 Transmitter |
| Sunovion Pharmaceuticals INC. | $65.58 | 2019-2020 | |
| Amgen INC. | $57.47 | 2024-2025 | Evenity, Otezla, Repatha |
| Takeda Pharmaceuticals U.S.A., INC. | $56.10 | 2019-2020 | |
| Exact Sciences Corporation | $46.24 | 2023-2025 | Cologuard Collection Kit |
| Corcept Therapeutics | $45.24 | 2022 | |
| Axsome Therapeutics, INC. | $40.32 | 2025 | Sunosi |
| Otsuka America Pharmaceutical, INC. | $37.17 | 2025 | Rexulti |
| Viatris Specialty LLC | $34.17 | 2025 | Yupelri |
| Phathom Pharmaceuticals, INC. | $32.53 | 2024 | Voquezna |
| Sanofi-Aventis U.S. LLC | $31.11 | 2021 | |
| Boston Scientific Corporation | $26.62 | 2022 | |
| Ge Healthcare | $25.38 | 2019 | |
| Abbvie INC. | $19.87 | 2024 | |
| Verona Pharma, INC. | $19.66 | 2025 | Ohtuvayre |
| Abbott Laboratories | $18.59 | 2020 | |
| Nestle Healthcare Nutrition INC. | $17.80 | 2022 | |
| Eisai INC. | $17.15 | 2021 | |
| Lundbeck LLC | $13.81 | 2023 | Rexulti |
| Optos, INC. | $13.31 | 2020 | |
| Avanir Pharmaceuticals, INC. | $11.99 | 2022 | |
| Athena Bioscience, LLC | $10.72 | 2023 | Qdolo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harry Garrett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.